Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Articles|September 16, 2022
Mental Health for Mental Health Professionals
Author(s)Psychiatric Times Editors
Tell us how you stay healthy and beat burnout for a chance to be featured in our Wellbeing Checkup video series.
Advertisement
Do you have a go-to method—or 2—for maintaining your mental and physical health? Psychiatric TimesTM wants to hear from you!
Contact us now to be featured in an upcoming episode of
If you would like to discuss your healthy habits in an upcoming episode of Wellbeing Checkup, write us at
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
2
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
The Psychiatric Pipeline in Review: Quarter 3, 2026
5